false 0000718937 0000718937 2022-06-07 2022-06-07

UNITED STATES

SECU RITI ES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pu rsuant to S e ction 13 or 15(d) of t he S ec u rities Exchange Act of 1934

Date of re port (Date of earli est e v e nt r e porte d): June 7, 2022

STAAR Surgical Company

(Exact Na me of Registrant as Specified in Charter)

Delaware | 0-11634 | 95-3797439
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.)
25651 Atlantic Ocean Drive Lake Forest, California |  | 92630
(Address of Principal Executive Offices) |  | (Zip Code)

Registrant’s Telephone Number, Including Area Code: 626-303-7902

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box bel ow if the Fo rm 8-K fili ng is i ntended to simultaneously satis fy the filing obligation of the registrant under any of the f ollo w i ng provisions (s ee General Instruction A.2. belo w):

☐ | Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ | Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ | Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common | STAA | NASDAQ

Indicate by check mark w h ether the registra nt is an e merg ing gro w th co mpany as defined in Rule 405 of the Sec urities Act of 1 933 (17 CFR §230.405) or Rule 12 b-2 of the Sec urities E x change Act of 1934 (17 CFR §240.12 b-2).

Emer g i ng g row th co m pany ☐

If an e merg ing gro wth co mpany, i ndicate by check mark if t he registrant has elected not to use t he exte nded transition period for compl y i ng w ith any n ew or revised fin a ncial accounting sta ndards provided pursuant to Section 13(a) of the Exch ange Act. ☐

Item 7.01 Regulation FD Disclosure.

Representatives of STAAR Surgical Company (the “Company”) will give presentations to investors commencing on June 7, 2022. A copy of the slide presentation they will share is furnished as Exhibit 99.1 to this Report and is incorporated herein by this reference.

Item 8.01 Other Events.

On June 7, 2022, the “Company published a press release reporting that more than two million Visian® Implantable Collamer lenses (“ICLs”) have been sold globally, a copy of which is furnished as Exhibit 99.2 to this report and is incorporated herein by this reference.

This information and the information contained in the presentation and press release shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in Item 7.01 and Item 8.01 of this Current Report, and Exhibits 99.1 and 99.2 are not incorporated by reference into any filings of STAAR made under the Securities Act of 1933, as amended, whether made before or after the date of this Current Report, regardless of any general incorporation language in the filing unless specifically stated so therein.

Item 9.01 Financial Statements and Exhibits

Exhibit No. |  | Description
99.1 |  | Slide presentation dated June 2022.
99.2 |  | Press Release dated June 7, 2022.
104 |  | Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

STAAR Surgical Company
June 7, 2022 | By: | /s/ Caren Mason
|  | Caren Mason
|  | President and Chief Executive Officer